synthetic biology

3 statements across 3 episodes · 1 bullish · 1 bearish · 2 people on the record · first statement Jan 18, 2022 by Ari Lipman · across every show →

Everything said about synthetic biology, oldest first

Jan 18, 2022 positive
Insight
Lipman: Synbio startups should prioritize niche, high-value markets
“You know, you always want to try to own a larger portion of a small market than try to own a small portion of a large market, at least at the outset. So I think, and that has been the tradition across the biotech industry and across synthetic biology is go for…”
Ari Lipman Jan 18, 2022 ▶ 30:24 Microbes, meat and materials: biotech meets climatetech
May 12, 2022 bearish
Assertion Supported
Kann: Synthetic biology faces a substantial bioreactor capacity shortage
“We're already facing today a fairly substantial bioreactor capacity shortage in that market.”
Shayle Kann May 12, 2022 ▶ 11:37 Shayle’s “ask me anything” episode
Feb 2, 2023 neutral
Insight
Kann: Synbio chemical startups succeed in high-value, low-volume niches
“What we've seen so far is some companies having a lot of success producing sort of More complex chemicals that are higher value, but smaller volume commodities. So solugen would be the sort of classic example of this. This is a private venture backed company w…”
Shayle Kann Feb 2, 2023 ▶ 6:51 Mailbag episode! Biotech, layoffs, battery recycling and more
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 200 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.